The Resonate Program Panel
Genetic blood test evaluating nearly 300 genes associated with sensorineural hearing loss to help identify an underlying genetic cause.
Accessed through the Resonate Sponsored Testing Program•Sponsored by Akouos, Eli Lilly•Performed by Prevention Genetics
Designed to support clinical decision-making and ordering in your practice.
For healthcare providers
Overview
The Resonate Program provides no-cost access to a 274-gene NGS panel for patients with auditory neuropathy or sensorineural hearing loss, enabling identification of genetic etiologies that may inform clinical management. Sponsored by Akouos and Eli Lilly and performed by Prevention Genetics, the program removes the cost barrier to comprehensive genetic workup in this population. De-identified data may contribute to prevalence research and therapeutic development.
When to consider this test
Patient selection
- Individuals in the United States (under 40 years of age) with at least one of the following:
- Bilateral or unilateral sensorineural hearing loss confirmed by ABR or behavioral testing (mild to profound)
- Auditory neuropathy
- Individuals in Brazil or Mexico (under 18 years of age) with at least one of the following:
- Bilateral sensorineural hearing loss confirmed by ABR or behavioral testing (severe or profound)
- Auditory neuropathy
Workflow
How to use this program
- 1
Confirm eligibility
Assess patient eligibility per country-specific criteria, review expectations for genetic testing, and discuss benefits and limitations with the family.
- 2
Order test
Order testing directly through the Resonate ordering portal or coordinate counseling and test ordering through InformedDNA for families needing additional guidance.
- 3
Collect and submit specimen
Collect the appropriate specimen and ensure containers are labeled with two identifiers. Ship to PreventionGenetics; specimens are accepted Monday–Saturday.
- 4
Review and communicate results
Results are available in 3–4 weeks from lab receipt. Review findings with the family and provide follow-up recommendations or referrals as needed.
Billing overview
Program billing
For eligible patients, the sponsor has arrangements with the laboratory that may reduce or cover some or all of the patient's out-of-pocket cost. Actual cost and patient responsibility vary by program criteria. Refer to lab or sponsor materials for details.
Quality & privacy
Laboratory quality & data handling
Testing is performed by Prevention Genetics, a CLIA-certified laboratory (CLIA 52D2065132) and College of American Pathologists (CAP) certified laboratory (CAP 7185561). Your sample is processed using validated methods and quality controls to support reliable genetic results.
Your health information is handled under privacy and security practices that are intended to align with applicable regulations. For program- and lab-specific details, review the privacy information provided by the laboratory and sponsor.
FAQ
Frequently asked questions
Which patients are appropriate for the Resonate Program's auditory neuropathy genetic testing panel?
The Resonate Program is designed for patients in the United States who have been diagnosed with sensorineural hearing loss or auditory neuropathy and who meet the program's eligibility criteria. Orders must be placed by a qualified healthcare provider. The program targets identification of underlying genetic etiologies using a comprehensive hearing-loss-focused panel.
What genes and methodology does the Resonate Program panel for hearing loss cover?
The Resonate Program Panel covers 274 genes associated with hearing loss, including TTR, using next-generation sequencing (NGS). The panel is performed by Prevention Genetics and is designed to provide a broad assessment of genetic causes of sensorineural hearing loss and auditory neuropathy.
What specimen type is required and what is the turnaround time for the Resonate auditory neuropathy panel?
The Resonate Program accepts buccal swab specimens. Expected turnaround time is 3 to 4 weeks from receipt of the sample at Prevention Genetics. This makes sample collection straightforward, particularly for pediatric patients or those for whom phlebotomy may be difficult.
Is there a prescribing or purchase obligation when ordering the Resonate hearing loss genetic test?
Ordering through the Resonate Program carries no prescribing or purchase obligation. The testing is fully sponsored by Akouos and Eli Lilly at no cost to the patient or the ordering provider. The program is intended solely to support clinical decision-making through genetic diagnosis.
Is genetic counseling included with the Resonate Program for auditory neuropathy patients?
Yes, the Resonate Program includes no-charge genetic counseling services alongside genetic testing. Counselors can assist with pre-test and post-test discussions, helping patients and families interpret results in the context of their clinical picture and potential management implications.
How is patient data handled in the Resonate auditory neuropathy testing program?
Data generated through the Resonate Program may be de-identified and used to support prevalence research and therapeutic development initiatives. No personally identifiable patient information is shared outside the performing laboratory without de-identification. This contributes to the broader understanding of genetic hearing loss while maintaining patient privacy.
Which patients are eligible for Resonate Auditory Neuropathy genetic testing?
Patients may qualify for Resonate if they meet the program's eligibility criteria:
- Individuals in the United States (under 40 years of age) with at least one of the following:
- Bilateral or unilateral sensorineural hearing loss confirmed by ABR or behavioral testing (mild to profound)
- Auditory neuropathy
- Individuals in Brazil or Mexico (under 18 years of age) with at least one of the following:
- Bilateral sensorineural hearing loss confirmed by ABR or behavioral testing (severe or profound)
- Auditory neuropathy
See an issue with this program?